March 2022 - Page 4 of 4 - BioMedWire (BMW)

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

FridayMar 04, 2022 9:30 am

Study Finds That Walkable Neighborhoods Decrease Prevalence of Diabetes, Obesity

A new study has found that individuals living in neighborhoods having access to outdoor activities and parks have a reduced chance of suffering from obesity or diabetes because the neighborhood residents are more active. Data shows that more than 11% of the U.S. population has diabetes with almost one-half of adults also suffering from obesity. Gillian L. Booth, colead author of the study, stated that the built environment influenced the levels of physical activity an individual undertook, through the promotion of active forms of transportation, such as cycling and walking, over passive ones, such as driving a car. The built…

ThursdayMar 03, 2022 9:30 am

Researchers Uncover Why Naked Mole Rats Live Long

A new study has found that naked mole rats demonstrate exceptional resistance to cancer and aging. Naked mole rats have long interested researchers involved in cancer research and aging research. Recently, researchers from the Kumamoto University in Japan succeeded in isolating stem cells from the brains of these rodents. In their report, the researchers explained how these cells helped maintain body homeostasis, which is important in cancer resistance and aging. Cancer and aging is caused by the depletion and dysfunction of tissue-specific stem cells, which are cells that differentiate to form specialized cells. These cells were found throughout the bodies…

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

WednesdayMar 02, 2022 9:30 am

Researchers to Study Why Music, Art Therapy Benefits Mental Health Patients

The National Endowment for the Arts is sponsoring an arts therapy initiative known as Creative Forces in partnership with the Department of Veterans Affairs and Department of Defense. Art therapies are increasingly being used to treat various brain conditions, including Alzheimer’s, Parkinson’s disease, depression and post-traumatic stress disorder. However, most of these therapies, ranging from poetry to music to visual arts, haven’t undergone exhaustive scientific testing. Brain researchers and artists have started an initiative called the NeuroArts Blueprint to conduct research into this. The initiative is the result of collaboration between the Aspen Institute’s Health, Medicine and Society Program, and…

WednesdayMar 02, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market

Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plant InMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022 Combination of complementary InMed and BayMedica business models key to increasing shareholders’ value In 2020, the global health and wellness market reached $4.436 trillion and is expected to grow at a CAGR of 5.5% from 2021 to 2030, resulting in an estimated value of $7.7 trillion by the end of the forecasted period (https://ibn.fm/BjCNi). The primary…

WednesdayMar 02, 2022 9:00 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) sugarBEAT(R) Wearable CGM Device Targets Billion-Dollar Global Diabetes Market

Global diabetes-related healthcare expenses are estimated at $966 billion in 2021 A recent report reveals 537 million adults currently live with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045 Glucose intake is an important factor in diabetes management, prevention and reversal NMRD’s sugarBEAT(R) wearable is a non-invasive, flexible CGM device helping diabetes and prediabetes patients monitor glucose levels NMRD’s MiBoKo metabolic health program recently launched, provides AI-powered insights based on glucose readings Diabetes is a primary driver of chronic disease costing the healthcare services sector more than $966 billion in 2021. Nemaura Medical (NASDAQ:…

TuesdayMar 01, 2022 9:30 am

New Study Investigates Negative Effects of Being Obsessively Passionate About Your Job

New research has explained why being obsessively passionate about one’s job may have maladaptive and negative outcomes for a person. University of Manitoba professor Benjamin Schellenberg, the lead author of the study, stated that obsessively passionate individuals reported lower levels of psychological well-being and also experienced more stress, anxiety and negative emotions. The researchers’ objective was to find out why obsessive passion was common in the workplace, despite these negative consequences. For their study, the researchers carried out a series of studies that evaluated lay beliefs about passion from a number of perspectives. Every participant in each study was instructed…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: March 2022

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Study Finds That Walkable Neighborhoods Decrease Prevalence of Diabetes, Obesity

Researchers Uncover Why Naked Mole Rats Live Long

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Researchers to Study Why Music, Art Therapy Benefits Mental Health Patients

InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market

Nemaura Medical Inc.’s (NASDAQ: NMRD) sugarBEAT(R) Wearable CGM Device Targets Billion-Dollar Global Diabetes Market

New Study Investigates Negative Effects of Being Obsessively Passionate About Your Job

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search